Big Returns For Oncology Investors
This article was originally published in Start Up
Patently successful and promising immune-oncology technologies, large markets, and attractive returns have factored into impressive investments in companies with cancer-targeting drugs or technologies. A five-plus-year study of fundraising for biopharma, medtech, and diagnostics companies, using deal data from Informa’s Strategic Transactions, indicates strong and steadily building investor confidence in the segment.
You may also be interested in...
Since 2013, investors have rallied around biotech IPOs like never before. START-UP looks at the current window and the implications of investor enthusiasm for newly public companies.
Start-Up surveyed investments into, and exits by, private infectious disease-focused companies from 2013 through the first quarter of 2016, using data from Informa’s Pharma Intelligence's Strategic Transactions and Medtrack databases. Our review reveals an increasing amount of money going into these firms, especially those developing novel antibiotics against drug-resistant bacteria or with novel anti-infective drug development platforms.
Investments in endocrine/metabolic disease-focused medtech companies reached a four-year high in 2015. Biopharma companies grabbed the majority of the funds that have been raised since 2012, and among medtechs, those focused on diabetes fared best.